BMS Decides Against Opdualag Launch In Germany
BMS says that recent reforms to the benefit assessment system have led to the “deterioration” of the German market.
You may also be interested in...
A new law aimed at limiting drug spending in Germany will mean that only companies with new products that offer high levels of added benefit will have full flexibility to negotiate prices.
'Dangerous’ new measures outlined in a leaked bill would be a disaster for orphan drugs and lead to companies opting out of the German market, says one industry executive.
Germany looks set to introduce new measures to curb pharmaceutical spending, including higher mandatory rebates for outpatient drugs and combination products. It will also lower the threshold at which orphan drugs must undergo a benefit assessment.